Celldex CEO Anthony Marucci Buys 375,000 Shares

Anthony Marucci, CEO of Celldex Therapeutics, Inc. (NasdaqCM: CLDX), recently purchased 375,000 shares of the company's stock. This insider transaction took place on June 25, 2026. The exact price of the purchase wasn't disclosed, but shares traded at $35.26 on Tuesday.

Insider Buying and Selling at Celldex Therapeutics, Inc.

On June 25, 2026, several insiders at Celldex Therapeutics made significant share purchases. Besides CEO Anthony Marucci, Senior Vice President and Chief Business Officer Ronald Pepin bought 20,000 shares, while Denice Torres and Neil Garry Arthur each acquired 26,000 shares. Senior Vice President and CFO Samuel Bates purchased 93,000 shares, and Margo Heath-Chiozzi, SVP of Regulatory Affairs, along with Sarah Cavanaugh, SVP of Corporate Affairs and Administration, each bought 95,000 shares. None of these transactions were part of pre-planned trading programs.

Other Institutional Activity in Celldex Therapeutics

Wellington Management Group increased its holdings in Celldex by 480,868 shares, ending with 8,560,476 shares valued at approximately $271.5 million, marking a 6% increase. Kynam Capital Management, however, trimmed its stake by 102,613 shares, now holding 5,840,567 shares worth about $185.3 million, a 1.7% decrease. BlackRock also reduced its position by 81,930 shares, retaining 5,369,885 shares valued at $170.3 million, down by 1.5%. Meanwhile, Point72 Asset Management significantly boosted its holdings by 1,471,582 shares, an 83.7% increase, bringing its total to 3,229,939 shares valued at $102.5 million. Vanguard Capital Management opened a new position with 2,960,895 shares, valued at around $93.9 million.

Celldex Therapeutics, Inc. Stock Down 9.9%

Shares of Celldex Therapeutics traded at $35.26 on Tuesday. The company has a market cap of approximately $2.77 billion. Its stock has a 52-week low of $19.52 and a high of $35.79. The 50-day moving average is $32.10, and the 200-day moving average is $28.27. Celldex's forward P/E ratio is not meaningful due to its lack of profitability, with a beta of 0.93. The company maintains a strong financial position with a current ratio of 8.92 and a quick ratio of 8.78, and a debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright & Co. reiterated its buy rating for Celldex with a price target of $42. UBS maintained its buy rating with a $45 target on June 10. Earlier, Wells Fargo also kept a buy rating with a $54 target on May 13. The consensus among analysts is a strong buy, with an average target price of $57.53 based on 15 analyst opinions.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies to treat severe inflammatory, allergic, autoimmune, and other diseases. The company's leading drug candidates include Barzolvolimab, a monoclonal antibody targeting chronic urticarias and other conditions, and CDX-622, a bispecific candidate for inflammatory diseases. Celldex is led by CEO Anthony S. Marucci and employs approximately 198 people.

Bottom Line

Anthony Marucci's recent purchase of shares in Celldex Therapeutics highlights insider confidence in the company's prospects. Investors often track such insider activity as a potential indicator of future performance. However, it's important to remember that this information is based on past transactions and may not reflect current positions.